FBT
FBT Fund Description
The First Trust NYSE Arca Biotechnology ETF tracks an equal-weighted index of US biotechnology stocks.
FBT Factset Analytics Insight
FBT is a popular choice among biotech funds, managing to accumulate substantial assets despite taking a somewhat unusual approach to the segment. The underlying index contains only 30 names (increased from 20 in October 2014), which is more limited than some other funds in the segment, such as IBB and XBI. Exposure includes access to pharmaceuticals and medical technology in addition to traditional biotech, with a higher small-cap and midcap presence than our segment benchmark. The bias away from larger firms stems from the equally weighted basket, an approach that’s not unusual. Still, FBT’s equal weighting of about 30 stocks produces a relatively concentrated basket. FBT trades well with reasonably tight spreads and remains a formidable name in the biotechnology sector.
FBT MSCI ESG Analytics Insight
The MSCI ESG Fund Quality Score measures the ability of ETF underlying holdings to manage key medium to long-term risks and opportunities arising from environmental, social, and governance factors, as determined by MSCI ESG Research LLC. As of April 23, 2018 the First Trust NYSE Arca Biotechnology Index Fund MSCI ESG Fund Quality Score is 4.30 out of 10.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. FBT ranks in the 18th percentile within its peer group and in the 14th percentile within the global universe of all funds in MSCI ESG Fund Metrics coverage.
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
FBT Top 10 Countries
FBT Top 10 Sectors
FBT Top 10 Holdings View All
FBT Portfolio Data
FBT Index Data
Related ETFs to FBT
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
FBT Portfolio Management
FBT Tax Exposures
FBT Fund Structure
FBT Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of FBT. FBT is rated a 5 out of 5.
FBT Tradability
FBT Sector/Industry BreakdownView All
FBT Top 10 HoldingsView All
FBT Geographic Exposure
FBT Performance Statistics
FBT MSCI ESG Ratings
FBT BENCHMARK COMPARISON
- FBT
- 30 Holdings
- Segment Benchmark
- 120 Constituents
- Shared Holdings
- 21 (Count)
- 34.33% (Weight)
Options Strategies for Outcome Investing
A collar strategy is a protective option strategy constructed by writing a call and buying a put with the same expiration date while being long the underlying security.
The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.
ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.
[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
Data provider:
Terms of Use
MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.